4-甲基-2-苯基-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1,3-噻唑 | 690632-24-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-甲基-2-苯基-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1,3-噻唑
• 中文别名: 3-噻唑；4-甲基-2-苯基-5-(4；4-甲基-2-苯基-5-(4,4,5,5-四甲基-1,3,2-二氧杂环己硼烷-2-基)-1,3-噻唑；2-二氧硼烷)-1
• 英文名称: 4-methyl-2-phenyl-5-boronic-1,3-thiazole acid pinacol ester
• 英文别名: 4-methyl-2-phenylthiazole-5-boronic acid pinacol ester；4-methyl-2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole；4-methyl-2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole
• CAS: 690632-24-7
• 化学式: C₁₆H₂₀BNO₂S
• 分子量: 301.217
• InChiKey: QJROOQWDMKQWEZ-UHFFFAOYSA-N

物化性质

• 熔点：
  75 °C
• 沸点：
  435.0±47.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.42
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-甲基-2-苯基-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1,3-噻唑 在 potassium hydrogen bifluoride 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 以83%的产率得到potassium 4-methyl-2-phenyl-5-(trifluoroborato)-1,3-thiazole
  参考文献：
  名称：

  铜介导的不饱和有机三氟硼酸钾的自由基三氟甲基化

  摘要：

  铜介导的不饱和有机三氟硼酸盐与 Langlois 试剂 (NaSO 2 CF 3 ) 和 TBHP 的三氟甲基化允许将三氟甲基引入各种有机亚结构中。该反应易于建立，条件温和且通用，并且该方法提供了获得三氟甲基化炔烃、烯烃、芳烃和杂芳烃的途径，收率相当到良好。

  DOI：

  10.1021/jo4023233

文献信息

• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE PHD, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：AKEBIA THERAPEUTICS INC

  公开号：WO2022036188A1

  公开（公告）日：2022-02-17

  The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

  本发明部分提供了PHD的新型小分子抑制剂，其结构符合公式（I），以及其子公式：或其药用可接受的盐。本文提供的化合物可用于治疗包括心脏（如缺血性心脏病、充血性心力衰竭和心瓣膜疾病）、肺（如肺部炎症、肺炎、急性肺损伤、肺动脉高压、肺纤维化和慢性阻塞性肺病）、呼吸系统（如呼吸道感染、急性呼吸窘迫综合征）、肝（如急性肝功能衰竭和肝纤维化和肝硬化）和肾（如急性肾损伤和慢性肾病）疾病、炎症性肠病（IBD）、缺血再灌注损伤（如中风）和早产儿视网膜病变（ROP）等疾病的治疗。
• HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：JACKSON Paul F.

  公开号：US20110105494A1

  公开（公告）日：2011-05-05

  This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R 2 , R 3 , and R 4 are as defined in the specification.

  这项发明涉及一种新型芳基吲哚嘧啶A及其治疗和预防用途。治疗和/或预防的疾病包括帕金森病。其中X、R2、R3和R4如规范中定义。
• Copper-Mediated Radical Trifluoromethylation of Unsaturated Potassium Organotrifluoroborates
  作者：Marc Presset、Daniel Oehlrich、Frederik Rombouts、Gary A. Molander

  DOI：10.1021/jo4023233

  日期：2013.12.20

  Copper-mediated trifluoromethylation of unsaturated organotrifluoroborates with the Langlois reagent (NaSO2CF3) and TBHP allows the introduction of trifluoromethyl groups into a variety of organic substructures. The reactions are easy to set up, the conditions are mild and general, and the process provides access to trifluoromethylated alkynes, alkenes, arenes, and heteroarenes in fair to good yields

  铜介导的不饱和有机三氟硼酸盐与 Langlois 试剂 (NaSO 2 CF 3 ) 和 TBHP 的三氟甲基化允许将三氟甲基引入各种有机亚结构中。该反应易于建立，条件温和且通用，并且该方法提供了获得三氟甲基化炔烃、烯烃、芳烃和杂芳烃的途径，收率相当到良好。